ABSTRACT
Explosive epidemics of chikungunya, Zika, and COVID-19 have recently occurred worldwide, all of which featured large proportions of subclinical infections. Spatial studies of infectious disease epidemics typically use symptomatic infections (cases) to estimate incidence rates (cases/total population), often misinterpreting them as infection risks (infections/total population) or disease risks (cases/infected population). We examined these three measures in a pediatric cohort (N≈3,000) over two chikungunya epidemics and one Zika epidemic and in a household cohort (N=1,793) over one COVID-19 epidemic in Nicaragua. Across different analyses and all epidemics, case incidence rates considerably underestimated both risk-based measures. Spatial infection risk differed from spatial disease risk, and typical case-only approaches precluded a full understanding of the spatial seroprevalence patterns. For epidemics of pathogens that cause many subclinical infections, relying on case-only datasets and misinterpreting incidence rates, as is common, results in substantial bias, a general finding applicable to many pathogens of high human concern.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants R01 AI099631 (AB), P01 AI106695 (EH), R01 AI120997 (AG), and U19 AI118610 (EH) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the National Institutes of Health Centers of Excellence for Influenza Research and Surveillance [contract: HHS 272201400006C (AG)]; and the Open Philanthropy Project Fund for the production of recombinant SARS-CoV-2 spike protein, its receptor binding domain, and antibodies at the University of Michigan Center for Structural Biology. FBC was partially supported by a supplement to grant P01 AI106695.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PDCS was approved by Institutional Review Boards of the University of California, Berkeley, the University of Michigan, Ann Arbor, and the Nicaraguan Ministry of Health. The HICS was approved by the University of Michigan, Ann Arbor and the Nicaraguan Ministry of Health. The parents or legal guardians of participants provided written informed consent. Subjects six years and older provided verbal assent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos